Scarica l'app Stockscreener
0.415
3.49%
0.014
Dopo l'orario di chiusura:
.42
0.005
+1.20%
Entero Therapeutics Inc Borsa (ENTO) Ultime notizie
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, ALVR, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM, LBRDA, ENTO, LLYVA on Behalf of Shareholders - GlobeNewswire Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders - AccessWire
ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc.ENTO - Marketscreener.com
Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum - The Manila Times
Entero Therapeutics announces proposed reverse merger with Journey Therapeutics - TipRanks
Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders - The Bakersfield Californian
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AE, LBRDA, PULM, ENTO on Behalf of Shareholders - The Malaysian Reserve
ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders - Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Entero, Journey to merge, creating oncology-focused biopharma By Investing.com - Investing.com Canada
Entero stock in focus amid reverse merger plans (ENTO:NASDAQ) - Seeking Alpha
Entero, Journey to merge, creating oncology-focused biopharma - Investing.com
Entero Therapeutics Announces Proposed Reverse Merger with - GlobeNewswire
Entero Therapeutics Announces 99% Reverse Merger Deal with Journey's Cancer Platform | ENTO Stock News - StockTitan
Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. in a reverse merger transaction. - Marketscreener.com
FIRST WAVE BIOPHARMA, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
AzurRx BioPharma, Inc. Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients - Marketscreener.com
AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients - Marketscreener.com
Layoff Tracker: Marinus Cuts Employees After Disappointing Phase III Trial - BioSpace
How Are Things Looking For Entero Therapeutics Inc. (NASDAQ: ENTO) For The Short Term? - Stocks Register
Entero therapeutics CFO sells shares to cover tax obligations By Investing.com - Investing.com South Africa
Entero therapeutics CFO sells shares to cover tax obligations - Investing.com India
Entero Therapeutics Inc.’s Market Journey: Closing Weak at 0.42, Down -19.41 - The Dwinnex
Taking on analysts’ expectations and winning: Entero Therapeutics Inc. (ENTO) - SETE News
Potential Price Increase for Entero Therapeutics Inc. (ENTO) After Recent Insider Activity - Knox Daily
Market cap of Entero Therapeutics Inc. [ENTO] reaches 1.95M – now what? - The DBT News
ENTO’s 2023 Market Dance: Down -85.72% – Time to Invest? - The InvestChronicle
Lexicon Pharmaceuticals (LXRX) Stock Surges Amid Positive Analys - GuruFocus.com
EMCOR Group (NYSE:EME) Sets New 12-Month High at $402.91 - Defense World
Evolus (NASDAQ:EOLS) Trading Down 2.9% - Defense World
Health Beat: Hope for children with EoE - 69News WFMZ-TV
Emmaus Life Sciences director buys $800 in company stock By Investing.com - Investing.com UK
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
EMCOR Group (NYSE:EME) Hits New 1-Year High at $402.91 - MarketBeat
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket - Benzinga
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics faces Nasdaq delisting over share price - Investing.com
Entero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Canoo Inc (NASDAQ: GOEV) Could Pass $4.5 In One Year Stock Forecast - Stocks Register
Understanding ENTO stock ratios for better investment decisions - US Post News
Entero Therapeutics Secures Exclusive Technology License - Investing.com
Entero Therapeutics Secures Exclusive Technology License By Investing.com - Investing.com Canada
Entero Therapeutics signs letter of intent with Data Vault Holdings - TipRanks
Entero Therapeutics Signs Letter of Intent to License and - GlobeNewswire
Entero Therapeutics appoints new independent accountant - Investing.com India
Entero Therapeutics appoints new independent accountant By Investing.com - Investing.com Canada
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):